
The new center represents AmerisourceBergen’s first facility erected specifically for clinical trial and commercial third-party logistics activities.

The new center represents AmerisourceBergen’s first facility erected specifically for clinical trial and commercial third-party logistics activities.

Market forces may limit the success of CMOs.

Nelson Patterson has been elected to Pharma & Biopharma Outsourcing Association board.

There are significant differences between small molecules and biologics fill/finish capacity.

Ligand-binding assays are fundamental to characterizing biosimilars.

Biomanufacturing capacity expansion uses modular cleanroom design and single-use technologies.

New organization offers support to contract research organizations and contract manufacturing organizations in the New England area.

Outsourcing is taking on a greater role in the biopharmaceutical manufacturing industry.

Grand River Aseptic Manufacturing has announced that the company executed two commercial production contracts in one day.

European CDMOs want into the US market, but entry options are limited.

The trend of exits from the CMO industry looks to be gaining momentum.

A dynamic market, industry consolidation, and demand fluctuations lead to a mixed picture of pricing results.

A Q&A on bioanalytical method integrity with Roger Hayes of MPI Research.

Representatives of contract service organizations discuss technology trends with BioPharm International.

Annual study shows geographic proximity not a factor in CMO selection.

A well-constructed quality agreement can be an important tool to enable effective collaboration between owner and CMO.

The author highlights the top 10 outsourcing trends found during a survey of biopharmaceutical manufacturers.

As payers refuse to cover new drugs, CMOs take a hit.

Aesica Pharmaceuticals S.r.I. collaborates with QAD to meet China's Food and Drug Administration's shortened serialization deadline.

With budgets growing, clients see CMOs' costs as less crucial.

Evolving clinical trial research services give biopharmaceutical companies options for full- and functional-services.

Biopharma companies should not overlook India's growing market.

The CMO industry's value proposition is limiting its market penetration.

Outsourcing activity remains strong and unlikely to abate, especially in more traditional areas.

Vetter launches new serialization process to support track-and-trace efforts.